Life sciences company Azenta (NASDAQ: AZTA) reported Q4 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $148.6 million. Its non-GAAP profit of $0.14 per share was in line with analysts’ consensus estimates.

Is now the time to buy AZTA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Azenta’s fourth quarter saw a flat sales trajectory, with revenue slightly ahead of Wall Street estimates but non-GAAP profit in line with expectations. The market responded negatively, reflecting investor concerns over operational setbacks, including persistent quality issues in automated stores and ongoing macroeconomic challenges. CEO John Marotta openly acknowledged that the turnaround journey remains uneven, citing ongoing efforts to remediate these issues and noting that cost pressures, especially in North America, weighed on margins. Marotta described the quarter as a transitional period, marked by cautious capital spending and delays in government and academic funding.

Looking ahead, Azenta’s management is focused on accelerating growth and margin expansion through operational improvements, continued investment in commercial and R&D capabilities, and a sharper strategic focus. Marotta reiterated the company’s confidence in achieving its full-year margin and growth targets, anticipating that delayed customer orders and recent quality remediations will translate into a stronger performance in the second half. CFO Laurence Flynn pointed to planned efficiency gains and a more favorable sales mix, especially as North America recovers, as key drivers of the company’s outlook, stating that "as our sales reps, particularly in North America, start to ramp, in the second half of the year, usually, you know, we brought in north of 25 reps. And usually, they take about three to six months to ramp. So that's kind of in our calculus."

Key Insights from Management’s Remarks

Management attributed the latest quarter’s performance to lingering operational issues, uneven regional demand, and the impact of macro-driven spending delays in key end markets.

• Automated stores quality issues: Persistent quality problems in automated storage solutions continued to weigh on margins and required direct remediation efforts, with CEO John Marotta noting most issues should be resolved by the end of the next quarter.
• North America lagging: The company experienced continued softness in North America due to slow capital spending, government shutdown impacts, and delays in academic and government funding, while Europe and Asia performed more robustly.
• Biorepositories and next-generation sequencing gains: Biorepositories and next-generation sequencing delivered solid growth, with management citing strong customer adoption and significant demand for advanced workflows, particularly in Asia.
• Sanger sequencing decline: Ongoing declines in Sanger sequencing, an older DNA sequencing technology, put pressure on the Multiomics segment, though management emphasized investments in next-generation solutions to offset this trend.
• Operational excellence initiatives: The Azenta Business System (ABS) and a decentralized operating structure were highlighted as central to driving efficiency, supporting margin recovery, and enabling focused investments in commercial and product innovation.

Drivers of Future Performance

Azenta’s outlook centers on operational improvements, margin recovery, and renewed commercial momentum, especially as delayed projects and investments are expected to materialize in the second half.

• Resolution of quality issues: Management expects that the remediation of automated store quality problems will be completed by mid-year, which should remove a major drag on gross margins and improve customer satisfaction.
• North America commercial rebound: The company is banking on a rebound in North American demand, supported by improved capital spending and renewed activity in academic and government sectors, with new sales hires expected to contribute after a ramp-up period.
• Efficiency and cost management: Operational efficiency initiatives, such as Kaizen events and automation in biorepositories, are anticipated to drive margin expansion and offset residual headwinds from underutilized lab capacity and regional sales mix.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) whether North America’s commercial rebound and capital spending materialize, (2) the resolution of automated store quality issues and their impact on gross margin, and (3) the effectiveness of operational efficiency initiatives, such as Kaizen events and automation in biorepositories. Further progress on new product introductions and execution of cost management plans will also be important indicators to track.

Azenta currently trades at $28.52, down from $36.89 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.